Alx Oncology Holdings (ALXO) Accumulated Expenses (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Accumulated Expenses data on file, last reported at $1.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 86.14% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (down 86.14% YoY), and the FY2025 full-year result was $14.4 million, up 171.81% from the prior year.
• Accumulated Expenses slipped to $1.8 million in Q1 2026, from $14.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $30.1 million in Q2 2024 to a low of $1.8 million in Q1 2026.
• A 5-year average of $9.1 million and a median of $4.8 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses jumped 624.57% in 2023 and sank 86.14% in 2026, its largest moves.
• Tracing ALXO's Accumulated Expenses over 5 years: stood at $3.7 million in 2022, then jumped by 624.57% to $26.9 million in 2023, then tumbled by 80.25% to $5.3 million in 2024, then soared by 171.81% to $14.4 million in 2025, then plunged by 87.49% to $1.8 million in 2026.
• Business Quant data shows ALXO's Accumulated Expenses at $1.8 million in Q1 2026, $14.4 million in Q4 2025, and $2.8 million in Q3 2025.